Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monomeric anti-FRα IgG1
- Development stage
- Preclinical
- Lead developer
- Medicovestor
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Monomeric anti-FRα IgG1 is a human monoclonal antibody targeting folate receptor alpha (FRα), isolated from a human phage display library. Developed by Medicovestor and Sanyou Biopharmaceuticals, this antibody serves as the structural building block for the ADoBind platform. In this platform, the monomeric IgG1 is engineered with an S444C mutation in the heavy chain to allow disulfide-bond crosslinking into a tetravalent format. As a standalone monomeric entity, the antibody binds to FRα-expressing cells and mediates antibody-dependent cellular cytotoxicity (ADCC). In preclinical studies, it has been used as a comparative control for the tetravalent antibody and the antibody-drug conjugate (ADC) MC001, demonstrating lower avidity, lower serum concentrations (AUC), and reduced anti-tumor potency compared to the multivalent versions in models of pancreatic and ovarian cancer.
- Other names
- monomeric FRα antibodymonomeric anti-folate receptor alpha IgG1monomeric IgG1 counterpart
02
Targets
FCGR1A (High affinity immunoglobulin gamma fc receptor I)FOLR1 (FRα)FcγRII/III (Low affinity immunoglobulin gamma Fc region receptor II and III)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on monomeric anti-FRα IgG1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monomeric anti-FRα IgG1.